high mcm3 expression is an independent biomarker of poor prognosis and correlates with reduced rbm3 expression in a prospective cohort of malignant melanoma高mcm3表达式是一个独立的不良预后的生物标志物和与减少rbm3表达式前瞻性群组的恶性黑色素瘤.pdfVIP

Nodin et al. Diagnostic Pathology 2012, 7:82 /content/7/1/82 RESEARCH Open Access High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma 1 1 1 2 3,4 1* Björn Nodin , Marie Fridberg , Liv Jonsson , Julia Bergman , Mathias Uhlén and Karin Jirström Abstract Background: Malignant melanoma is the most lethal form of skin cancer with a variable clinical course even in patients with thin melanomas and localized disease. Despite increasing insights into melanoma biology, no prognostic biomarkers have yet been incorporated into clinical protocols. Reduced expression of the RNA binding motif protein 3 (RBM3) has been shown to correlate with tumour progression and poor prognosis in melanoma and several other cancer forms. In ovarian cancer, an inverse association was found between expression of RBM3 and the minichromosome maintenance 3 (MCM3) gene and protein. In melanoma, gene expression analysis and immunohistochemical validation has uncovered MCM3 as a putative prognostic biomarker. The aim of the present study was to examine the associations of MCM3 expression with clinical outcome and RBM3 expression in a prospective, population-based cohort of melanoma. Methods: Immunohistochemical MCM3 expression was examined in 224 incident cases of primary melanoma from the Malmö Diet and Cancer Study, previously analysed for RBM3 expression. Spearman´s Rho and Chi-Square tests were used to explore correlations between MCM3 expression, clinicopathological factors, and expression of RBM3 and Ki67. Kaplan Meier analysis, the log rank test, and univariable and multivariable Cox proportional hazards model